Sanofi India News

Intimation of closure of trading window

Change in Senior Management Personnel. Kindly refer to the enclosed file for details.

Appointment of Senior Management Personnel. Kindly refer to the enclosed file for details.

The Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Allotment of shares pursuant to the Scheme of Arrangement between Company and Sanofi Consumer Healthcare India Limited

The Company has approved issue of duplicate share certificates request in lieu of the original share certificates reported lost/misplaced.

The Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Adani group companies and LTTS, among others, are in focus for corporate actions like dividends and AGMs this week.

Please find enclosed a copy of the minutes

Every now and then the market goes through phases, where it prefers a certain set of stocks, not based on sector but based on the overall market cap. So, sometimes it is large caps, at other mid-caps. Now this partially happens, due to the flows which are coming to markets. For example, if more flows are coming to mid-cap or multicap schemes there is bound to be out performance in the mid-cap space. Now what it does is that it tends to create a sudden surge in mid-cap. Similarly when there is an outflow like the kind of one which we saw in March this year, midcap stocks tend to decline sharply. Essentially, it is the flows which impact the broader matrix of how midcaps behave. So there are phases not owning a midcap stocks appeared to sin and then there phase, where owning them appears to be sin. But if one focuses on the underlying business and some critical parameters, there is a possibility of getting rid of these phases of anxiety which keep coming to the street and create long term wealth.

Intimation of Record Date for the purpose of ascertaining the Shareholders of the Demerged Company who will be entitled to receive fully paid-up equity shares of Rs. 10/- each of the Resulting Company pursuant to the Scheme of Arrangement.

Effectiveness of the Scheme of Arrangement between Sanofi India Limited and Sanofi Consumer Healthcare India Limited

The Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

The Company has approved issue of duplicate share certificates request in lieu of the original share certificates reported lost/ misplaced.

The Company has received communication from its Registrar and Share Transfer Agent on loss of Share Certificate(s)

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Please find enclosed copies of the Notice to Shareholders of the Company regarding transfer of shares to IEPF, published on 17th May 2024.

Please find enclosed herewith transcript of the Investors/ Analysts Call scheduled on 16th May 2024.

Please find enclosed Scrutinizer''s Report issued by M/s MMJB & Associates LLP, Company Secretaries, on the Remote E-Voting and E-Voting conducted at the Annual General Meeting held on 14th May 2024.

Please find enclosed herewith the presentation made to the Investors/ Analysts at the Investor/ Analyst Call held today i.e. 16th May 2024.

Summary of proceedings of the 68th Annual General Meeting of the Company

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Unaudited standalone and consolidated financial results for the quarter ended 31st March 2024.

We wish to inform you that the Board of Directors at its meeting held today i.e. Monday, 13th May 2024, based on the recommendation of the Nomination and Remuneration Committee, have approved the appointment of Mr. Eric Mansion as a Non-Executive Director of the Company with effect from 3rd June 2024, subject to the approval of the Members of the Company through Postal Ballot.

We refer to our letter dated 26th April 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Monday, 13th May 2024, inter-alia considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended 31st March 2024.

59 companies, including Zomato and Varun Beverages, to reveal Q4 results for March 2024. Jindal Steel, Tube Investments, AB Capital also share earnings. Zomato expects 75% y-o-y revenue growth, 48% q-o-q net profit rise.

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced.

Judicial pronouncement by the Hon''ble National Company Law Tribunal, Mumbai bench, approving the Scheme of Arrangement ("Scheme") between Sanofi India Limited and Sanofi Consumer Healthcare India Limited ("NCLT Order").

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company will hold an investor / analysts call on Financial Results for the Quarter ended 31st March 2024 on 16th May 2024 at 2:00 p.m. Kindly refer to the attachment for details of the call.

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for adults with obesity and type 2 diabetes to improve glycemic control.

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 19074.08 Crore) operating in Pharmaceuticals sector.

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, We would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 ,inter alia, to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the Quarter ended 31st March 2024.

The Notice of the Annual General Meeting and E-Voting information of the Company published today i.e. 23rd April 2024 , in newspapers, Business Standard and Sakal.

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s).

Business Responsibility and Sustainability Report for the year 2023

Pursuant to Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Report for the Financial Year ended 31st December 2023 along with the Notice of the 68th Annual General Meeting (AGM) which is scheduled to be held on 14th May 2024 through Video Conferencing facility / Other Audio-Visual Means, for your information and records.

Notice of the Sixty Eighth Annual General Meeting of Sanofi India Limited to be held on May 14, 2024 at 3:30 p.m. (IST) through Video Conferencing/ Other Audio-Visual Means.

Pursuant to Regulation 39(3) of SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced,.